KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Debt to Equity (2016 - 2020)

Historic Debt to Equity for Neogenomics (NEO) over the last 12 years, with Q1 2020 value amounting to $0.19.

  • Neogenomics' Debt to Equity fell 3469.06% to $0.19 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.19, marking a year-over-year decrease of 3469.06%. This contributed to the annual value of $0.19 for FY2019, which is 3613.74% down from last year.
  • Neogenomics' Debt to Equity amounted to $0.19 in Q1 2020, which was down 3469.06% from $0.19 recorded in Q4 2019.
  • Neogenomics' Debt to Equity's 5-year high stood at $0.6 during Q2 2018, with a 5-year trough of $0.19 in Q1 2020.
  • Its 5-year average for Debt to Equity is $0.33, with a median of $0.3 in 2018.
  • In the last 5 years, Neogenomics' Debt to Equity surged by 8058.87% in 2017 and then tumbled by 6607.57% in 2019.
  • Quarter analysis of 5 years shows Neogenomics' Debt to Equity stood at $0.46 in 2016, then dropped by 10.12% to $0.41 in 2017, then fell by 26.98% to $0.3 in 2018, then tumbled by 36.14% to $0.19 in 2019, then dropped by 0.8% to $0.19 in 2020.
  • Its Debt to Equity was $0.19 in Q1 2020, compared to $0.19 in Q4 2019 and $0.2 in Q3 2019.